- Home
- CCTG vs NXTC Comparison
CCTG vs NXTC Comparison
Compare CCTG & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCTG
- NXTC
- Stock Information
- Founded
- CCTG 1993
- NXTC 2015
- Country
- CCTG Hong Kong
- NXTC United States
- Employees
- CCTG N/A
- NXTC N/A
- Industry
- CCTG
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- CCTG
- NXTC Health Care
- Exchange
- CCTG Nasdaq
- NXTC Nasdaq
- Market Cap
- CCTG 14.9M
- NXTC 13.9M
- IPO Year
- CCTG 2024
- NXTC 2019
- Fundamental
- Price
- CCTG $1.10
- NXTC $0.46
- Analyst Decision
- CCTG
- NXTC Strong Buy
- Analyst Count
- CCTG 0
- NXTC 2
- Target Price
- CCTG N/A
- NXTC $3.50
- AVG Volume (30 Days)
- CCTG 5.9K
- NXTC 338.3K
- Earning Date
- CCTG 08-23-2025
- NXTC 07-31-2025
- Dividend Yield
- CCTG N/A
- NXTC N/A
- EPS Growth
- CCTG N/A
- NXTC N/A
- EPS
- CCTG N/A
- NXTC N/A
- Revenue
- CCTG $16,463,490.00
- NXTC N/A
- Revenue This Year
- CCTG N/A
- NXTC N/A
- Revenue Next Year
- CCTG N/A
- NXTC N/A
- P/E Ratio
- CCTG N/A
- NXTC N/A
- Revenue Growth
- CCTG 3.27
- NXTC N/A
- 52 Week Low
- CCTG $0.99
- NXTC $0.22
- 52 Week High
- CCTG $3.17
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- CCTG 45.98
- NXTC 45.99
- Support Level
- CCTG $1.05
- NXTC $0.45
- Resistance Level
- CCTG $1.12
- NXTC $0.49
- Average True Range (ATR)
- CCTG 0.04
- NXTC 0.07
- MACD
- CCTG 0.01
- NXTC -0.01
- Stochastic Oscillator
- CCTG 70.00
- NXTC 4.63
About CCTG CCSC Technology International Holdings Limited
CCSC Technology International Holdings Ltd along with its subsidiaries is involved in the sale, design, and manufacturing of interconnect products, including connectors, cables, and wire harnesses. Its products include customized interconnect products, including connectors, cables, and harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. Geographically, the company generates maximum revenue from the sale of its products in Europe and the rest from the Americas and Asia.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.